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Abstract 
Background: General practitioners in the UK are financially incentivized, via the Quality 
Outcomes Framework, to maintain a record of all patients at their practice with HF and 
manage them appropriately. The prevalence of heart failure (HF) recorded in primary care 
registers (0.7-1.0%) is less than reported in epidemiological studies (3-5%). Using an audit of 
clinical practice, we set out to investigate if there are patients “missing” from primary care 
HF registers and what the underlying mechanisms might be. 
Design: Audit of clinical practice at a UK General Practice (N=9390).  
Methods: Audit software (ENHANCE-HF®) identified patients who may have HF via a series 
of hierarchical searches of electronic records. HF was then confirmed or excluded based on 
the electronic records by a HF specialist nurse and patients added to the register. Outcome 
data for patients without HF was collected after 2 years. 
Results: HF prevalence was 0.63% at baseline and 1.12% after the audit. Inaccurate coding 
accounted for the majority of missing patients. Amongst patients without HF who were 
taking a loop diuretic, the rate of incident HF was 13% and the rate of death or 
hospitalization with HF was 25% respectively during 2 year follow up.  
Conclusion: There are many patients missing from community HF registers which may 
detriment patient outcome and practice income. Patients without HF who take loop 
diuretics are at high risk of HF related events. 
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Main text 
 
Introduction 
Heart failure with reduced ejection fraction (HeFREF) affects 3.5-7.0% in patients aged 65-
75,1,2 and up to 11% of those >80.3,4 Heart failure with normal ejection fraction (HeFNEF) 
accounts for at least half of heart failure diagnoses.5,6 The current overall prevalence of 
HeFNEF and HeFREF is estimated to be 4.9% and 3.3% respectively.7 Prevalence is expected 
to rise with an ageing population.8-10 
There are multiple interventions proven to prolong life in patients with HeFREF.11 
Consequently, general practitioners (GPs) in the United Kingdom are financially incentivized 
by the Quality Outcomes Framework (QOF) to maintain a register of patients with heart 
failure and to manage them appropriately.12 
The prevalence of heart failure, measured by the proportion of patients within a practice 
population on a heart failure register, is much lower than expected from epidemiological 
reports; approximately 0.7-1.0%.13 The reasons for this are unknown; one possible 
explanation is for the discrepancy is that the clinical features of heart failure are non-specific 
and common which may lead to misdiagnosis.4,14 Incomplete or incorrect electronic coding 
may also play a role.  
To investigate, we performed an audit of clinical practice at a single GP surgery in the UK 
using an electronic audit tool and a dedicated heart failure specialist nurse (HFSN). Our 
primary aim was to discover why patients may be missing from community heart failure 
registers and not a cost-benefit analysis of the process of identifying patients and increasing 
the numbers of patients on the register. 
 
Methods 
The practice 
Montague Medical Practice in Goole, East Yorkshire has 5 GP partners serving a patient 
population of around 9300 (table 1).15 The practice uses SystmOne electronic records 
software. A piece of audit software, ENHANCE-HF® [Oberoi Consulting, Derby, UK], was 
installed at the practice and a dedicated HFSN (ACG) was placed on site to help manage any 
patients identified as having heart failure. The project ran as an audit of the practice’s 
activity from April to December 2015, further data collection was undertaken in April 2017. 
  
ENHANCE-HF® 
The software performed a series of searches on the electronic database (table 2). Patients 
with heart failure or who may have heart failure were identified by QOF Read codes, old 
Clinical Terms Version 3 (CTV3) Read codes or Clinical Terms Version 29 (CTV29) Read codes 
in their electronic record. 
The searches identified patients who were either on the current heart failure register or 
recorded as having left ventricular systolic dysfunction (LVSD), as well as patients with other 
Read codes relating to heart failure or left ventricular failure (LVF). It also identified patients 
without Read codes relating to heart failure but with features suggesting the diagnosis: 
those with a high serum natriuretic peptide, those taking angiotensin converting enzyme 
inhibitors (ACEI), angiotensin receptor blockers (ARB), beta-blockers (BB), mineralocorticoid 
receptor antagonists (MRA), loop diuretics or sinus node blockers.16  
 
Follow-up 
2 years after completion of the initial project, follow up data was collected for patients who 
were part of the audit. “Heart failure” was confirmed if there was evidence in the electronic 
records of either: 
• an echocardiogram showing mild-moderate LVSD or worse in conjunction with 
symptoms of breathlessness or ankle swelling  
• a letter from a cardiology specialist confirming the diagnosis 
• a hospital discharge summary with heart failure as either a primary or secondary 
diagnosis. 
 
Audit Cycle 
 
Step one  
The software searches found all patients on the heart failure and LVSD registers. Electronic 
records of these patients were then reviewed by the HFSN to confirm the diagnosis. Patients 
on the LVSD register but not the heart failure register were added if the diagnosis was 
confirmed. Finally, the software identified patients who had outdated Read codes relating to 
LVSD. Patients’ records were reviewed and the patient added to the appropriate registers if 
the diagnosis was confirmed. 
 
Step two 
Using a hierarchical series of steps, the software then identified patients who were not on 
the heart failure or LVSD registers but who fell into one of the following (mutually exclusive) 
groups:  
• raised serum natriuretic peptides (NPs) on record 
o Brain natriuretic peptide (BNP) >100pg/mL 
o N-terminal peptide of prohormone of brain natriuretic peptide (NT-pro-BNP) 
>400 pg/mL 
• taking digoxin in combination with ACEi/ARB  
• taking an MRA or ivabradine,  
• assigned Read codes relating to LVF or heart failure.  
• taking a combination of beta-blocker, ACEi and loop diuretic.  
The HFSN reviewed the case notes of all patients identified. Those with signs, symptoms or 
results (cardiomegaly on chest x-ray, raised NPs) consistent with heart failure were referred 
for echocardiography.  Patients with high serum NPs taken >3 months ago were referred for 
repeat blood tests. Patients with high serum NPs and atrial fibrillation (with no other sign, 
symptom or result suggestive of heart failure) were not included.  
Finally, patients not on the register who had results or correspondence that confirmed heart 
failure (such as reduced left ventricular ejection fraction on echocardiogram or a letter 
confirming diagnosis from a cardiologist) were added to the register. 
 
Step three 
The final step involved identification of patients who were not on the heart failure or LVSD 
register but who fell into one of the following groups: 
• Patients taking loop diuretic  
• Patients taking loop diuretic and ACEi or ARB 
• Patients taking loop diuretic and BB 
 
Again, those with results or correspondence confirming HF in the electronic record were 
added to the HF register. Those with signs, symptoms or results suggestive of HF were 
referred for further investigation and added to the register if the diagnosis was confirmed.  
 
Results  
A total of 276 patients was identified by the searches (total practice n=9390; 2.9%) at 
baseline: 59 of these were on the heart failure register giving a prevalence of 0.63% for the 
practice.  
 
Step 1 
There were 14 patients on the LVSD register and 2 patients with old LVSD Read codes who 
were not on the HF register. 1 patient was on the heart failure register in error and was 
removed. After corrections, the number of patients on the heart failure register increased to 
74 (prevalence 0.79%). 
 
Step 2 
Step 2 identified 106 patients with possible heart failure based on drug use. 53 patients had 
raised NPs. 48 patients were taking a combination of ACEi/ARB, BB, MRA, loop diuretics, 
digoxin or ivabradine. 5 patients who were not on the register had Read codes relating to 
LVF or heart failure in their records (but not the LVSD Read code) (figure 1). 
Of the 106 patients: 
• 17 had a diagnosis of heart failure on the electronic records and were added to the 
register.  
• 62 did not have findings suggestive of heart failure in their records; 
• 23 patients were referred for further investigation:  
o heart failure was confirmed in 7 patients,  
o heart failure excluded in 9 patients  
o 7 patients did not have investigations completed 
• 3 patients died before being assessed 
• 1 patient had had Read codes for LVF assigned in error.  
Step 2 thus identified an additional 24 patients with heart failure, bringing the total on the 
register now to 98 (prevalence 1.04%). 
 
Step 3  
Step 3 identified a further 95 patients who were taking a loop diuretic. 37 patients were 
taking loop diuretics alone, 48 patients were taking loop diuretic and ACEi/ARB and 10 
patients were taking loop diuretic and BB (figure 1).  
Of the 95 patients: 
• 75 patients did not have signs, symptoms or results suggestive of heart failure in 
their records  
• 4 patients had a diagnosis of heart failure on the electronic records and were added 
to the register.  
• 16 patients were referred for further investigation:  
o heart failure confirmed in 2 patients;  
o heart failure excluded in 8 patients; and  
o 6 patients did not have investigations completed.  
Step 3 thus identified an additional 6 patients with heart failure bringing the total on the 
register now to 104 (prevalence 1.12%). 
 
Loop diuretics 
Steps 2 and 3 identified 109 patients who were not on the heart failure or LVSD register at 
baseline but were taking loop diuretics either alone or in combination with other 
medications. Of these 109 (14 from step 2 and 95 from step 3), 15 were added to the heart 
failure register at the end of the project.  
Of the remaining 94 patients who were not diagnosed with heart failure by the initial audit 
(table 3):  
• 22% of patients had complained of oedema at consultations during the audit period.  
• 15% had complained of breathlessness at consultations during the audit period.  
• 20% had a record of a condition that may be associated with peripheral oedema 
such as hypothyroidism 
• 36% were taking a calcium channel blocker 
The rate of incident heart failure at 2 years was 13%, all-cause mortality was 23%, giving a 
rate of heart failure hospitalization or death of 25%. 
 
Discussion 
Our results are consistent with comparisons between epidemiological reports and QoF data: 
a significant number of patients with heart failure is missing from a representative primary 
care register. Using a staged process, mostly using an automated system, a total of 45 
patients was added to the heart failure register.  
Absent or incomplete Read codes accounted for the majority of missing patients in the 
practice (n=36); possibly a consequence of the ever-changing ways in which patients can be 
coded for various symptoms or conditions on electronic records. 
Accurate coding allows GPs to identify patients at increased risk of adverse outcome.  Strict 
adherence to guidelines, such as up-titration of medications to maximum tolerated doses, 
improves outcome in patients with heart failure.17-19 Absent or incomplete coding may 
mean that some patients with heart failure are missed and their care may suffer as a result. 
Patients who take loop diuretics without a diagnosis of heart failure are at significant risk of 
adverse outcome related to heart failure. Loop diuretics are first line treatment for venous 
congestion in heart failure,20 but peripheral oedema is not always cardiogenic. 
Consequently, diuretic use is common and not isolated to patients with HF.21-23 Treatment 
with diuretic agents, such as chlorthalidone, reduce the incidence of heart failure in those at 
risk. 24 However, diuretics may mask the signs and symptoms of heart failure with which 
patients present, thus reducing the recorded incidence without treating the underlying 
disease, and delaying diagnosis which may lead to poorer outcomes as a consequence.25 
The prevalence of heart failure at the end of the project is still less than expected from 
epidemiological reports. In our audit, the majority of patients taking loop diuretics without a 
diagnosis of heart failure did not qualify for further investigation as there was no record of 
signs or symptoms of the diagnosis. However, if loop diuretics are masking the features that 
would prompt further investigation, the prevalence of heart failure among those taking loop 
diuretics may be much higher.  
The National Institute for Health Research Collaboration for Leadership in Applied Health 
Research and Care in Greater Manchester ran similar projects between 2008 and 2013 with 
the Greater Manchester Heart Failure Investigation Tool (GM-HFIT).26 This also found heart 
failure prevalence to be much lower than expected at baseline and used the GM-HFIT audit 
tool to identify patients with possible heart failure and increase prevalence (table 4).26 Our 
audit found a higher prevalence of heart failure using ENHANCE-HF® audit software (1.12%).  
It may be argued that our results, combined with the GM-HFIT results, suggest the actual 
prevalence of heart failure is lower than epidemiological studies predict. Indeed, some 
studies have suggested the rate of over-diagnosis of heart failure may be as high as 17-18% 
in general practice.27 However, we only found only 1 patient recorded incorrectly on the HF 
register. Furthermore, heart failure may be undiagnosed in a large proportion of elderly 
patients with clinical signs of the disease.2,4,14,28,29 We think that it is more likely that heart 
failure is under-recognised in the community (as we have demonstrated) rather than the 
prevalence over-estimated by epidemiological studies. 
 
Clinical implications 
Audit tools, such as ENHANCE-HF®, can identify patients who may be missing from heart 
failure registers and increase patients numbers on registers. Patients who take loop 
diuretics without a diagnosis of heart failure are at high risk of adverse outcome. The need 
for loop diuretics in such patients should be reviewed and appropriate investigations 
arranged should there be the suspicion of heart failure.  
 
Strengths and limitations 
Our project demonstrates that incorrect electronic coding is the main reason why patients 
may be missing from primary care heart failure registers and that patients who take a loop 
diuretic without a diagnosis of heart failure are at high risk of heart failure events; it is 
plausible that loop diuretics may disguise symptoms of heart failure thus delaying diagnosis 
and treatment. We have also demonstrated a simple method for assessing a practice 
population for patients who may be missing from the heart failure register.  Identifying such 
patients may increase practice income via the QOF framework and may improve patient 
outcome; most of the gain came from automated computer searches of existing practice 
registers. However, our work was never intended to provide a cost-benefit analysis of the 
process.   
However, our work was never intended to provide a cost-benefit analysis of the process nor 
may it be generalizable to all practices. Furthermore, the benefits of being on a heart failure 
register are merely implied by current evidence: access to specialist services in the 
community may improve outcomes,30 but there is limited evidence that maintaining a heart 
failure register per se improves outcomes or guideline adherence.  
The cut-offs for natriuretic peptides we used were based on National Institute for Clinical 
Excellence guidelines. European Society of Cardiology heart failure guidelines use far lower 
cut-offs (>125 pg/mL for NTproBNP; >35 pg/mL for BNP) which would surely increase the 
number of patients identified in further audits.11 Finally, we were unable to comment on the 
proportion of patients with HeFNEF as such information was not included on the heart 
failure register or hospital correspondence. 
 
 
 
Conclusions 
Heart failure registers identify patients with complex care needs, management plans and 
poor outcomes. Epidemiological studies suggest there are many patients with heart failure 
missing from primary care registers, this may be primarily due to absent or inaccurate 
electronic coding rather than under-diagnosis. The widespread use of loop diuretics in 
patients without heart failure may mask the disease, delay diagnosis and negatively impact 
outcome as a result; such patients seem to be at high risk of heart failure events.  
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Figure title and caption 
Figure 1 
Title: Patients added to the heart failure register 
Legend: Schematic of the ENHANCE-HF® audit process and the number of patients identified 
at each step. 
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